The second ten years: Long-term risks of breast conservation in early breast cancer

Kurtz, John M.; Amalric, R; Delouche, G; Pierouin, Bernard; Roth, Jakob; Spitalier, J. M.

doi:10.1016/0360-3016(87)90224-0

Cited by 70 publications

(27 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2,[21][22][23][24][25][26][27][28][29][30] At ten years, overall survival has ranged from 67 to 88 percent depending upon the stage of the disease ( control within the treated breast with primary tumors less than or equal to 5 cm in diameter (Table 7). 1,2,[22][23][24]27,28,[31][32][33][34][35][36][37][38] At ten years, local recurrence rates range from 8 to 19 percent. For patients with negative margins of resection, the ten-year actuarial risk of breast recurrence is 10 percent or less.…”

Section: Nonrandomized Studiesmentioning

confidence: 99%

Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma

Morrow

Strom

Bassett

et al. 2002

CA: A Cancer Journal for Clinicians

298

165

View full text Add to dashboard Cite

Multidisciplinary guidelines for management of invasive breast carcinoma from the American College of Radiology, the American College of Surgeons, the College of American Pathology, and the Society of Surgical Oncology have been updated to reflect the continuing advances in the diagnosis and treatment of invasive breast cancer. The guidelines provide a framework for clinical decision‐making for patients with invasive breast carcinoma based on review of relevant literature and include information on patient selection and evaluation, technical aspects of surgical treatment, techniques of irradiation, and follow‐up care.

show abstract

Section: Nonrandomized Studiesmentioning

confidence: 99%

Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma

Morrow

Strom

Bassett

et al. 2002

CA: A Cancer Journal for Clinicians

298

165

View full text Add to dashboard Cite

show abstract

“…Behçet hastalığında kullanılan kolşisin, prednizolon ve azotiopürinin kanser gelişimini indüklediği düşünülmektedir (1)(2)(3). Bu yazıda, Behçet seyri sırasında gelişen meme kanseri olgusu sunuldu.…”

Section: Sayın Editörunclassified

“…Behçet hastalığının seyrinde meme kanseri gelişimi için altta yatan nedenin otoimmün bozukluğun veya tedavide kullanılan ilaçların kanseri indüklediği düşünülmektedir (1,2). Bu hastada, Behçet hastalığı ile meme kanserinin tesadüfen birlikte olduğu düşünüldü.…”

Section: Sayın Editörunclassified

An Invasive Ductal Carcinoma in Behcet's Disease

Cihan¹

2012

Acta Oncol Tur.

View full text Add to dashboard Cite

“…The long-term risk of contralateral breast cancer has been found to be about 1% a year postmastectomy irrespective of whether radiation therapy was given or not (140). During the first 5 years after breast-conservative irradiation the chance of a new ipsilateral breast cancer is about half the risk of a contralateral one (59), after which the risk seems to be about 1% a year for each (143,146). However, long-term follow-up studies are needed to assess whether this would also be the case with relatively young patients living for several decades following their treatment.…”

Section: Risk Associated With Radiation Therapy After Lumpectomymentioning

confidence: 99%

Treatment of Early Breast Cancer with Conservation of the Breast a Review

1991

Acta Oncologica

View full text Add to dashboard Cite

This paper reviews the current status of conservative treatment for early breast cancer. While the first patients were treated with such techniques more than 60 years ago, it is during the last decade that randomized trials have confirmed that such treatment is comparable to mastectomy in preventing breast cancer death. Radiotherapy to the breast after local tumour excision is important to prevent local breast relapse, but it is not clear whether it has any influence on the risk of distant metastases. Several questions remain to be answered. While most investigators agree that the breast should receive a radiation dose of about 50Gy in 5 weeks, there is no general agreement about the need for a tumour bed booster dose. Considering patients with tumour infiltration at the surgical resection line for whom it is not possible for cosmetic reasons to perform re-resection, it is not clear whether an acceptable local control rate can be achieved through application of a high booster dose in the tumour bed. More trials are needed to show whether certain patients with small invasive carcinomas should be treated with wide local excision without radiotherapy. The need for radiotherapy after local excision for small intraductal (ductal carcinoma in situ) cancers is being addressed in ongoing trials.Key words: Breast cancer, breast conserving therapy, local relapse risk, review.The term 'breast-conserving treatment' includes techniques by which radical eradication of an early breast cancer (TI -2, NO-I, MO) is achieved without ablation of the mammary gland. Such treatment techniques have attracted widespread interest and recently become accepted alternatives to more radical and mutilating surgical procedures. The possibility of treating limited breast cancers, without breast ablation was suggested more than 60 years ago. Hirsch. (1) in Berlin and Keynes (2) in London published their first results in 1927 and 1929 respectively. Mustakallio (3) in Helsinki published his first series in 1945, and the Institute Curie group headed by Baclesse published their results in 1949 (4). The preliminary results achieved by these pioneers suggested that survival after breastconserving treatment could be similar to that achieved after radical mastectomy. This view gained further support when a follow-up paper from St. Bartholomew's Hospital (5) in 1953 reported long-term survival to be similar among the patients treated conservatively by Keynes and breast cancer patients treated in the same hospital with mastectomy. During the 1960s more authors reported encouraging results with breast-conserving treatment (6-9). and during the last two decades multiple reports have been published:1. The survival rate and risk of distant metastases following breastconserving therapy and mastectomy have been compared in randomized trials. 2.Long-term ( > 25 years) follow-up reports containing large numbers of patients have provided important information on long-term survival and risk of locoregional failure. These studies also give important informat...

show abstract

The second ten years: Long-term risks of breast conservation in early breast cancer

Cited by 70 publications

References 32 publications

Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma

Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma

An Invasive Ductal Carcinoma in Behcet's Disease

Treatment of Early Breast Cancer with Conservation of the Breast a Review

Contact Info

Product

Resources

About